To characterize the safety and antitumor activity of investigational immunotherapy agents in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Approach:
Study Design: Single-center, retrospective cohort study conducted at The University of Texas MD Anderson Cancer Center.
Patient Eligibility: Adults (≥18 years) with histologically confirmed HNSCC treated with novel immunotherapy agents in early-phase trials from January 1, 2015, to May 31, 2025.
Safety Assessment: Incidence and severity of treatment-related adverse events (TRAEs) graded according to Common Terminology Criteria for Adverse Events, version 5.0.
Antitumor Activity Assessment: Measured by objective response rate (ORR), clinical benefit rate (CBR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Key Findings:
Immune checkpoint inhibitors (ICIs) have reshaped treatment for recurrent or metastatic HNSCC but durable benefits remain limited.
Less than 20% of patients achieve long-term survival, highlighting the need for expanded therapeutic options.
Emerging ICIs targeting LAG-3, TIM-3, and TIGIT aim to overcome immune exhaustion.
Cytokine-based therapies and cellular therapies are among the novel strategies being explored.
Interpretation:
The unique immunobiology of HNSCC may influence the response and toxicity profiles of immunotherapy agents.
Limitations:
The study is retrospective and conducted at a single center, which may limit generalizability.
Safety and antitumor activity of investigational agents remain incompletely defined.
Conclusion:
A clear understanding of the clinical activity and safety of next-generation immune modulators is needed as the field advances beyond PD-1 and PD-L1 targeting.
